 DEERFIELD, Ill., June 14, 2021 GLOBE NEWSWIRE -- Surgalign Holdings, Inc. Surgalign NASDAQ: SRGA, a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, today announced that the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 28,985,508 shares of its common stock and warrants to purchase up to an aggregate of 28,985,508 shares of its common stock at a purchase price of 1.725 per share of common stock and related warrant. The warrants have an exercise price of 1.725 per share, will be immediately exercisable, and will expire three 3 years from the issuance date. The registered direct offering was priced at-the-market under Nasdaq rules. 